Dermasensor, Inc.


Developer of a handheld point-of-care optical spectroscopy device and associated machine-learning algorithm for non-invasive assessment of suspicious skin lesions. The company combines elastic scattering spectroscopy (ESS) hardware, a locked FDA-cleared AI algorithm, clinical study evidence, cloud device management, and customer support to enable rapid objective risk outputs to inform referral decisions in primary care and other outpatient settings.

Industries

N/A

Nr. of Employees

small (1-50)


Patents

Dynamic calibration of light intensity in a system for non-invasive detection of skin cancer using elastic scattering spectroscopy

US-12053263-B2

View Details

Optical process and apparatus for non-invasive detection of melanoma

US-11298025-B2

View Details

Optical process and apparatus for non-invasive detection of melanoma

US-9788730-B2

View Details

Products

Handheld optical spectroscopy skin lesion assessment device

A wireless, ergonomically designed handheld probe that records multiple spectral measurements from skin lesions and produces an instant objective malignancy risk output using an embedded algorithm.


Services

Consultant-guided support for payer documentation, coding guidance and claims submission processes through a reimbursement partner.

Provision of IFU, quick-reference guides, e-learning courses and on-demand customer support to train clinical staff on device operation.

Personalized on-site or virtual demos to show device operation, clinical workflow integration, and performance characteristics.

Expertise Areas

  • Optical spectroscopy for tissue assessment
  • Machine learning for clinical diagnostics
  • Prospective clinical study conduct and clinical utility evaluation
  • Regulatory strategy for medical devices (FDA clearance and Breakthrough Device pathway)
  • Show More (2)

Key Technologies

  • Elastic scattering spectroscopy (ESS)
  • Supervised machine learning for diagnostic scoring
  • Handheld optical probe hardware
  • Spectral data acquisition and signal processing
  • Show More (2)

News & Updates

Company scheduled to attend and provide device demos at a national clinical meeting.

Company scheduled to exhibit and provide demos at ACGME conference.

Press release summarizing results from pivotal clinical studies showing high sensitivity and reduced missed melanomas in primary care workflows.

Public announcements of awards and third-party recognition for device and company innovation.

Device achieved FDA clearance for automated skin cancer detection and received Breakthrough Device designation during regulatory process.

Completed multiple development, validation and clinical utility studies scanning several thousand lesions with published presentations and posters.

View All News

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.